TIDMCREO

RNS Number : 3290N

Creo Medical Group PLC

23 September 2019

Creo Medical Group plc

("Creo" or the "Company")

Notice of results

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, will announce its interim results for the six months ended 30 June 2019 on Monday, 30 September 2019.

 
 Creo Medical Group plc                                          investors.creomedical.com 
 Richard Rees (CFO)                                                    +44 (0)1291 606 005 
 
 Cenkos Securities                                                     +44 (0)20 7397 8900 
 Stephen Keys / Cameron MacRitchie 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com 
 Paul McManus                                                     Mob: +44 (0)7980 541 893 
 Lianne Cawthorne                                                 Mob: +44 (0)7515 909 238

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar RF for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes that its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORXXLFLKKFFBBZ

(END) Dow Jones Newswires

September 23, 2019 09:16 ET (13:16 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Creo Medical Charts.